March 12th marked the three year anniversary of the first quarantine order by the U.S. Government as a result of the outspread of the COVID-19 virus.
Photo Credit: Shutterstock
The COVID-19 pandemic has had a profound impact on the world and has led to an unprecedented level of attention on the pharmaceutical industry. With millions of lives at stake, pharmaceutical companies have been in the spotlight for their efforts to develop effective treatments and vaccines for the virus. However, the industry has also faced significant legal challenges, particularly in relation to the pricing and availability of COVID-19 treatments and vaccines.
Three years later, here is a look at some of the major court cases which ensued as a result of the global pandemic.
Remdesivir Patent Dispute
Remdesivir is an antiviral drug that was initially developed to treat Ebola but has since been repurposed for use in COVID-19 patients. The drug was developed by Gilead Sciences, and in March 2020, the company applied for a patent for the drug in India. However, the patent was challenged by several Indian pharmaceutical companies, who argued that the drug was not a new invention and did not meet the criteria for a patent. In November 2020, the Indian patent office rejected Gilead’s patent application, opening the door for Indian companies to manufacture and sell generic versions of the drug.
AstraZeneca Vaccine Supply Dispute
AstraZeneca is one of the leading manufacturers of COVID-19 vaccines, and its vaccine has been authorized for use in many countries around the world. However, the company has faced significant criticism for its handling of the vaccine’s supply chain. In January 2021, the European Union (EU) announced that it would be implementing export controls on vaccines produced within its borders, including the AstraZeneca vaccine. This move was in response to a dispute with AstraZeneca, which had announced that it would be unable to deliver the number of doses it had promised to the EU. The dispute has led to legal action, with the EU threatening to sue AstraZeneca for breach of contract.
Johnson & Johnson Talcum Powder Lawsuits
While not directly related to COVID-19, the Johnson & Johnson talcum powder lawsuits are significant for their potential impact on the pharmaceutical industry. Johnson & Johnson has faced thousands of lawsuits in recent years, with plaintiffs alleging that the company’s talcum powder products contain asbestos and have caused cancer. In February 2021, the company agreed to pay $100 million to settle over 1,000 talcum powder lawsuits. While this settlement does not relate directly to COVID-19, it highlights the importance of product liability and the potential financial impact of legal disputes on pharmaceutical companies.
Moderna Vaccine Patent Dispute
Moderna is another leading manufacturer of COVID-19 vaccines, and the company has faced a patent dispute over its vaccine technology. In September 2020, the University of Pennsylvania and the Rockefeller University filed a lawsuit against Moderna, claiming that the company had used technology developed by the universities without permission. The lawsuit alleges that Moderna’s COVID-19 vaccine uses a technique called messenger RNA, which was developed by scientists at the universities. Moderna has denied the allegations and has stated that it has its own proprietary technology.
